Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) RPS6KA2 Antibodies:
anti-Human RPS6KA2 Antibodies:
anti-Mouse (Murine) RPS6KA2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal RPS6KA2 Primary Antibody for IF, IHC (p) - ABIN562719
Passariello, Gayanilo, Kritzer, Thakur, Cozacov, Rusconi, Wieczorek, Sanders, Li, Kapiloff: p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in ?-tropomyosin Glu180Gly transgenic mice. in American journal of physiology. Heart and circulatory physiology 2013
RSK1 (show RPS6KA1 Antibodies) and 3 but not RSK2 (show RPS6KA3 Antibodies) are down-regulated in breast tumour and are associated with disease progression. RSK (show RPS6KA1 Antibodies) may be a key component in the progression and metastasis of breast cancer.
Data indicate that S6 kinase 2 (S6K2 (show RPS6KB2 Antibodies)) can phosphorylate histone H3 (show HIST3H3 Antibodies) at position Thr45, which may play a role during cell proliferation and/or differentiation.
Kinome screening revealed RPS6KA2 expression, in human pancreatic cancer cells, protects against erlotinib induced apoptosis.
genetic association study in Han population in China: Data suggest that SNPs in RSK3 (rs2229712) and in MEK1 (show MAP2K1 Antibodies) (rs28730804) demonstrate gene-gene interaction that affects antidepressant drug outcome in female patients with major depressive disorder.
Overexpression of RSK3 or RSK4 (show RPS6KA6 Antibodies) supports tumor cell proliferation upon PI3K (show PIK3CA Antibodies) inhibition both in vitro and in vivo therby contributing to drug resistance.
p90RSK2 is dispensable for BCR-ABL (show ABL1 Antibodies)-induced myeloid leukemia (show BCL11A Antibodies), but may be required for pathogenesis and lineage determination in FLT3 (show FLT3 Antibodies)-internal tandem duplication-induced hematopoietic transformation.
Data show that genetic variation in RPS6KA1 (show RPS6KA1 Antibodies), RPS6KA2, and PRS6KB2 were associated with risk of developing colon cancer while only genetic variation in RPS6KA2 was associated with altering risk of rectal cancer.
Characterization of the terminal domain as a protein kinase
chronic activation CREB (show CREB1 Antibodies) and p90RSK (show RPS6KA1 Antibodies) in the epileptic hippocampus may be closely associated with the histopathological changes of Ammon's horn sclerosis
The accumulation of S6K2 in the nuclei of cancer cells and the correlation with the expression of PCNA and Ki-67 suggest the involvement of S6K2 in the regulation of malignant growth
We confirmed that Raf1 (show RAF1 Antibodies)(L613V) knock-in confers a NS-like phenotype, including cardiac hypertrophy. Active RSK3 was increased in Raf1 (show RAF1 Antibodies)(L613V) mice. Constitutive RSK3 gene deletion prevented the Raf1 (show RAF1 Antibodies)(L613V)-dependent concentric growth in width of the cardiac myocyte and attenuated cardiac hypertrophy in female mice.
RSK3 is required for the induction of interstitial cardiac fibrosis in alpha-tropomyosin (show TPM1 Antibodies) Glu180Gly transgenic mice.
Anchored RSK3 transduces signals that modulate pathologic myocyte growth in cardiac hypertrophy.
p90RSK2 is dispensable for BCR-Abl (show ABL1 Antibodies)-induced myeloid leukemia (show BCL11A Antibodies), but may be required for pathogenesis and lineage determination in Flt3 (show FLT3 Antibodies)-internal tandem duplication-induced hematopoietic transformation.
activation and translocation of p90 (show GPAM Antibodies) ribosomal S6 protein kinase (show CDK7 Antibodies) requires RANTES (show CCL5 Antibodies)-mediated chemokine (show CCL1 Antibodies) transcription in astrocytes
p90Rsk2 and Emi1 functionally interact during oocyte maturation
inhibition of p90RSK (show RPS6KA1 Antibodies) prevented H2O2-mediated cTnI (show TNNC1 Antibodies) (Ser (show SIGLEC1 Antibodies)(23/24)) phosphorylation but not ERK1/2 (show MAPK1/3 Antibodies) and PKCalpha (show PKCa Antibodies)/betaII activation
p90RSK (show RPS6KA1 Antibodies) is a novel regulator of cardiac NHE1 (show SLC9A1 Antibodies) activity by phosphorylating NHE1 (show SLC9A1 Antibodies) serine 703 and a new pathological mediator of I/R injury in the heart
there is a functional link between S6K1 (show RPS6KB1 Antibodies) II and CK2 (show CSNK2A1 Antibodies) signaling, which involves the regulation of S6K1 (show RPS6KB1 Antibodies) II nuclear export by CK2 (show CSNK2A1 Antibodies)-mediated phosphorylation of Ser (show SIGLEC1 Antibodies)-17
RSK2 (show RPS6KA3 Antibodies) is a key regulator for cell transformation induced by tumor promoters such as EGF (show EGF Antibodies) and TPA (show PLAT Antibodies).
This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 non-identical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
ribosomal protein S6 kinase alpha-2
, ribosomal protein S6 kinase, 90kD, polypeptide 2
, 90 kDa ribosomal protein S6 kinase 2
, MAP kinase-activated protein kinase 1c
, MAPK-activated protein kinase 1c
, MAPKAP kinase 1c
, p90-RSK 2
, ribosomal S6 kinase 3
, ribosomal protein S6 kinase alpha 2
, S6K-alpha 2
, protein-tyrosine kinase Mpk-9